This is a work sharing model for the co-ordinated assessment of a generic application that has been filed with multiple Access Consortium agencies.
Similar Posts
Class 3 Medicines Recall: Glenmark Pharmaceuticals Europe Limited, Fingolimod Glenmark 0.5 mg Hard Capsules, EL(26)A/02
Glenmark Pharmaceuticals Europe Limited is recalling one batch after stability testing showed out-of-specification results. The batch is being recalled as a precautionary measure following test results that showed a delay in capsule dissolution.
Transparency data: Medicines and Healthcare products Regulatory Agency Privacy Notice
This privacy notice describes how we collect and use your personal information, in accordance with the Data Protection Act and the General Data Protection Regulation.
Brensocatib licensed as the first medicine specifically designed to treat non-cystic fibrosis bronchiectasis in patients 12 years and older
As with any medicine, the MHRA will keep the safety and effectiveness of brensocatib under close review.
Class 2 Medicines Recall: Mercury Pharmaceuticals Ltd, Paliperidone Mercury Pharma prolonged-release suspension for injection in pre-filled syringes, EL(26)A/01
Mercury Pharmaceuticals Ltd is recalling remaining stock of paliperidone pre-filled syringes as a precautionary measure due to Good Manufacturing Practice (GMP) deficiencies cited during a recent inspection at the finished product manufacturing site.
MHRA scientists contribute to international study on novel oral polio vaccine stability
Study confirms vaccine being used in global efforts to achieve and sustain polio eradication is successfully interrupting polio outbreaks whilst minimising risk of new vaccine-derived outbreaks in Uganda
Class 4 Medicines Defect Notification: Lexon UK Ltd, Moclobemide 150mg tablets, EL(25)A/50
Lexon UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the cartons for the batches listed in this notification is missing important updated safety information.